Novartis International AG http://www.novartis.com Three Scientists to Receive Prestigious Novartis Prizes for Immunology at 15th International Congress of Immunology 2013-06-17T07:15:00 CET http://www.novartis.com/newsroom/media-releases/en/2013/1709714.shtml Novartis drug Jakavi® improved overall survival of myelofibrosis patients and impacted an underlying mechanism of disease 2013-06-16T08:00:00 CET http://www.novartis.com/newsroom/media-releases/en/2013/1709669.shtml Switching to Novartis drug Gilenya from standard interferon shown to improve long-term outcomes for patients with multiple sclerosis 2013-06-10T07:15:00 CET http://www.novartis.com/newsroom/media-releases/en/2013/1708034.shtml New data at ENS show Novartis drug Gilenya benefited patients by improving all four key measures of multiple sclerosis 2013-06-05T07:15:00 CET http://www.novartis.com/newsroom/media-releases/en/2013/1707070.shtml Novartis Breakthrough Therapy LDK378 shows a marked clinical response in patients with ALK+ non-small cell lung cancer 2013-06-03T17:30:00 CET http://www.novartis.com/newsroom/media-releases/en/2013/1706664.shtml Novartis pivotal Phase III trial shows Afinitor® significantly delays tumor growth in HER2 positive advanced breast cancer 2013-06-02T15:00:00 CET http://www.novartis.com/newsroom/media-releases/en/2013/1706489.shtml Lucentis® receives positive opinion for patients with myopic choroidal neovascularization showing vision gains with only two injections 2013-05-31T13:21:10 CET http://www.novartis.com/newsroom/media-releases/en/2013/1706060.shtml World MS Day: Novartis launches a new campaign to raise awareness of MS and the unique experiences of people living with the disease 2013-05-29T07:25:00 CET http://www.novartis.com/newsroom/media-releases/en/2013/1705346.shtml Novartis highlights new findings in advancing care for patients with 170 abstracts in breast, lung and blood cancers at ASCO and EHA 2013-05-29T07:15:00 CET http://www.novartis.com/newsroom/media-releases/en/2013/1705343.shtml Key vildagliptin data in The Lancet show for the first time individualized HbA1c treatment goals can be reached in elderly type 2 diabetes patients with no major tolerability issues 2013-05-23T14:49:56 CET http://www.novartis.com/newsroom/media-releases/en/2013/1704156.shtml